Effects of vedolizumab in Japanese patients with Crohn’s disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses

BACKGROUND: Vedolizumab is a gut-selective humanized antibody that binds the α(4)β(7) integrin. We evaluated efficacy and safety of vedolizumab in Japanese patients with moderate-to-severe Crohn’s disease (CD). METHODS: In this Phase 3, double-blind study (NCT02038920), 157 patients were randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Kenji, Motoya, Satoshi, Ogata, Haruhiko, Kanai, Takanori, Matsui, Toshiyuki, Suzuki, Yasuo, Shikamura, Mitsuhiro, Sugiura, Kenkichi, Oda, Kazunori, Hori, Tetsuharu, Araki, Takahiro, Watanabe, Mamoru, Hibi, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Original Article—Alimentary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026209/
https://www.ncbi.nlm.nih.gov/pubmed/31836930
http://dx.doi.org/10.1007/s00535-019-01647-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026209/
https://www.ncbi.nlm.nih.gov/pubmed/31836930
http://dx.doi.org/10.1007/s00535-019-01647-w

Ejemplares similares